4015.SR | Ticker Profile

4015.SR

Jamjoom Pharmaceuticals Factory Company

Healthcare · ·

$157.10

Data: 2026-05-28

✓ ETHICAL PASS

MODERATE MOAT

MODERATE

Data Confidence: 57.1%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.9B

Total market value of the company

Trailing P/E

24.04

Premium valuation

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

+5.2%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Jamjoom Pharmaceuticals Factory Company

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceuticals.

Country: Saudi Arabia Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

N/A

Core business does not involve prohibited activities

Debt Ratio

0.0%

Debt must be below 33% of total assets

Cash Ratio

0.0%

Interest-bearing cash below 33% of assets

Receivables

0.0%

Receivables below 49% of assets

Revenue Purity

0.0%

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$25.50

What our model estimates this business is worth per share

Margin of Safety

-516.0%

Trading above fair value — no margin of safety

Rating

Overall assessment combining ethics, valuation, and quality

Percentile

30.2th

Ranks in the top 70% of our 13,571 screened universe

Ethical Score

N/A

Valuation Score

33.0

Quality Score

43.8

Combined

32.9

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.507

Good returns relative to risk taken

Kelly Fraction

-0.0206

No positive edge detected — the data suggests staying out

Calmar Ratio

0.322

Drawdown risk outweighs the returns — higher risk profile

Annual Return

11.4%

Historical annualised return based on price data

Max Drawdown

-35.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$1.70

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

35.8%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go